Geeta Gyamlani1, Praveen K Potukuchi2,3, Fridtjof Thomas4, Oguz Akbilgic5, Melissa Soohoo6, Elani Streja6, Adnan Naseer1, Keiichi Sumida2, Miklos Z Molnar2,7,8, Kamyar Kalantar-Zadeh6, Csaba P Kovesdy9,10. 1. Nephrology Section, Memphis Veterans Affairs Medical Center, Memphis, Tennessee, USA. 2. Division of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee, USA. 3. IHOP, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA. 4. Division of Biostatistics, Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA. 5. Center for Biomedical Informatics, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA. 6. Division of Nephrology, University of California, Irvine, California, USA. 7. Division of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, Tennessee, USA. 8. Division of Transplant Surgery, Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA. 9. Nephrology Section, Memphis Veterans Affairs Medical Center, Memphis, Tennessee, USA, ckovesdy@uthsc.edu. 10. Division of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee, USA, ckovesdy@uthsc.edu.
Abstract
BACKGROUND: To determine the association of vancomycin with acute kidney injury (AKI) in relation to its serum concentration value and to examine the risk of AKI in patients treated with vancomycin when compared with a matched cohort of patients receiving non-glycopeptide antibiotics (linezolid/daptomycin). METHODS: From a cohort of > 3 million US veterans with baseline estimated glomerular filtration rate ≥60 mL/min/1.73 m2, we identified 33,527 patients who received either intravenous vancomycin (n = 22,057) or non-glycopeptide antibiotics (linezolid/daptomycin, n = 11,470). We examined the association of the serum trough vancomycin level recorded within the first 48 h of administration with subsequent AKI in all patients treated with vancomycin and association of vancomycin vs. non-glycopeptide antibiotics use with the risk of incident AKI. RESULTS: The overall multivariable adjusted ORs of AKI stages 1, 2, and 3 in patients on vancomycin vs. non-glycopeptides were 1.1 (1.1-1.2), 1.2 (1-1.4), and 1.4 (1.1-1.7), respectively. When examined in strata divided by vancomycin trough level, the odds of AKI were similar or lower in patients receiving vancomycin compared to non-glycopeptide antibiotics as long as serum vancomycin levels were ≤20 mg/L. However, in patients with serum vancomycin levels > 20 mg/L, the ORs of AKI stages 1, 2, and 3 in patients on vancomycin vs. non-glycopeptide antibiotics were 1.5 (1.4-1.7), 1.9 (1.5-2.3), and 2.7 (2-3.5), respectively. CONCLUSIONS: Vancomycin use is associated with a higher risk of AKI when serum levels exceed > 20 mg/L.
BACKGROUND: To determine the association of vancomycin with acute kidney injury (AKI) in relation to its serum concentration value and to examine the risk of AKI in patients treated with vancomycin when compared with a matched cohort of patients receiving non-glycopeptide antibiotics (linezolid/daptomycin). METHODS: From a cohort of > 3 million US veterans with baseline estimated glomerular filtration rate ≥60 mL/min/1.73 m2, we identified 33,527 patients who received either intravenous vancomycin (n = 22,057) or non-glycopeptide antibiotics (linezolid/daptomycin, n = 11,470). We examined the association of the serum trough vancomycin level recorded within the first 48 h of administration with subsequent AKI in all patients treated with vancomycin and association of vancomycin vs. non-glycopeptide antibiotics use with the risk of incident AKI. RESULTS: The overall multivariable adjusted ORs of AKI stages 1, 2, and 3 in patients on vancomycin vs. non-glycopeptides were 1.1 (1.1-1.2), 1.2 (1-1.4), and 1.4 (1.1-1.7), respectively. When examined in strata divided by vancomycin trough level, the odds of AKI were similar or lower in patients receiving vancomycin compared to non-glycopeptide antibiotics as long as serum vancomycin levels were ≤20 mg/L. However, in patients with serum vancomycin levels > 20 mg/L, the ORs of AKI stages 1, 2, and 3 in patients on vancomycin vs. non-glycopeptide antibiotics were 1.5 (1.4-1.7), 1.9 (1.5-2.3), and 2.7 (2-3.5), respectively. CONCLUSIONS:Vancomycin use is associated with a higher risk of AKI when serum levels exceed > 20 mg/L.
Authors: Lindsey Pritchard; Catherine Baker; James Leggett; Paul Sehdev; Allen Brown; K Bruce Bayley Journal: Am J Med Date: 2010-12 Impact factor: 4.965
Authors: Michael J Rybak; Ben M Lomaestro; John C Rotschafer; Robert C Moellering; Willam A Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine Journal: Clin Infect Dis Date: 2009-08-01 Impact factor: 9.079
Authors: John A Bosso; Jean Nappi; Celeste Rudisill; Marlea Wellein; P Brandon Bookstaver; Jenna Swindler; Patrick D Mauldin Journal: Antimicrob Agents Chemother Date: 2011-09-26 Impact factor: 5.191
Authors: Elvira O Gosmanova; Miklos Z Molnar; Ahmed Alrifai; Jun L Lu; Elani Streja; William C Cushman; Kamyar Kalantar-Zadeh; Csaba P Kovesdy Journal: Am J Nephrol Date: 2015-09-24 Impact factor: 3.754
Authors: Morgan E Grams; Yingying Sang; Josef Coresh; Shoshana H Ballew; Kunihiro Matsushita; Andrew S Levey; Tom H Greene; Miklos Z Molnar; Zoltan Szabo; Kamyar Kalantar-Zadeh; Csaba P Kovesdy Journal: J Am Soc Nephrol Date: 2016-02-08 Impact factor: 10.121